Industry Focus
Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:31:15
- Mas informaciones
Informações:
Sinopsis
Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter
